Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543075 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function
A Phase 1 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00543075 is a Phase 1 study that has completed, run by Genta Incorporated. The registered enrollment target is 23 participants.
The verdict
NCT00543075, a Phase 1 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
Interventions
- DRUG Genasense (oblimersen, G3139)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543075
The ClinicalTrials.gov registry entry for NCT00543075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genasense (oblimersen, G3139) is the first listed.
NCT00543075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543075 about?
NCT00543075 is a clinical study titled "Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function". To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).
What is the current status of trial NCT00543075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00543075?
The interventions under investigation include: Genasense (oblimersen, G3139) (DRUG).
Who is sponsoring clinical trial NCT00543075?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.